Last reviewed · How we verify

MgSO4 plus Ropivacaine

Hospital Universiti Sains Malaysia · FDA-approved active Small molecule

Magnesium sulfate enhances the local anesthetic effect of ropivacaine by potentiating neural blockade and reducing pain transmission.

Magnesium sulfate enhances the local anesthetic effect of ropivacaine by potentiating neural blockade and reducing pain transmission. Used for Regional anesthesia and analgesia (peripheral nerve blocks, epidural anesthesia), Postoperative pain management.

At a glance

Generic nameMgSO4 plus Ropivacaine
SponsorHospital Universiti Sains Malaysia
Drug classLocal anesthetic adjuvant combination
TargetVoltage-gated sodium channels (ropivacaine); NMDA receptors and calcium channels (magnesium sulfate)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Magnesium acts as a natural NMDA receptor antagonist and modulates calcium influx in nerve cells, which synergizes with ropivacaine's sodium channel blockade to prolong anesthesia duration and improve anesthetic efficacy. This combination is used in regional anesthesia to achieve superior sensory and motor blockade with potentially reduced systemic toxicity of the local anesthetic agent.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: